Suppr超能文献

拉丁美洲国家的胎儿和新生儿溶血病及恒河猴同种免疫:一项范围综述

Hemolytic disease of the fetus and newborn and Rhesus alloimmunization in Latin American countries: a scoping review.

作者信息

Júnior Mário Dias Corrêa, Sosa Salvador Espino Y, Fernandes Milene, do Carmo Lais, de Oliveira Renato Watanabe, Kanevsky Gabriela

机构信息

Department of Obstetrics and Gynecology, Minas Gerais Federal University, Campus Health, Av. Prof. Alfredo Balena, 190 - Santa Efigênia, Belo Horizonte, MG, 30130-100, Brazil.

Clinical Research Department, Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes, Mexico City, Mexico.

出版信息

BMC Pregnancy Childbirth. 2024 Dec 20;24(1):830. doi: 10.1186/s12884-024-07044-3.

Abstract

BACKGROUND

Hemolytic disease of the fetus and newborn (HDFN) is a condition due to maternal blood group antibodies targeting antigens in fetal red blood cells, with significant prenatal/perinatal morbidity and mortality. Severe HDFN cases are often associated with alloimmunization against Rhesus D (RhD) or Kell antigens. Information about HDFN epidemiology and treatment in Latin American countries is limited. This review aims to identify and synthesize the available evidence on the epidemiology and management of HDFN in this region.

METHODS

In July 2023, EMBASE, PubMed, LILACS, and other databases were searched for articles reporting epidemiology, treatment, prenatal and perinatal outcomes, and patient journey of HDFN cases in Latin American countries. A snowball search of cross-references and gray literature complemented the initial search. Publications in English, Spanish, and Portuguese were reviewed. Data were extracted using a defined template and charted in tables.

RESULTS

We reviewed five guidelines and 19 observational studies from Brazil, Chile, Mexico, Argentina, Colombia, Panamá, Paraguay, and Peru. HDFN due to Rh alloimmunization ranged from 0.5 to 5 per 1000 live births, and anti-D remains the most frequent alloantibody type for severe HDFN. The perinatal mortality rate of HDFN is approximately 1.3-1.6 per 100,000 live births, and fetal deaths can reach 30% among patients treated with intrauterine transfusions. Up to 47% of alloimmunized pregnancies were referred to reference centers only during the third trimester. About 60% of eligible pregnancies received anti-D IgG prophylaxis.

CONCLUSIONS

Although estimates in LATAM countries are scarce and lack standardized measures, we observed that the incidence, morbidity, and mortality of HDFN in this region are problematic. RhD alloimmunization was reported in approximately up to 70% of severe HDFN cases, despite anti D HDFN being largely preventable.

摘要

背景

胎儿及新生儿溶血病(HDFN)是一种由于母体血型抗体靶向胎儿红细胞抗原而导致的疾病,具有显著的产前/围产期发病率和死亡率。严重的HDFN病例通常与针对恒河猴D(RhD)或凯尔抗原的同种免疫有关。拉丁美洲国家关于HDFN流行病学和治疗的信息有限。本综述旨在识别和综合该地区HDFN流行病学和管理的现有证据。

方法

2023年7月,检索了EMBASE、PubMed、LILACS和其他数据库,以查找报告拉丁美洲国家HDFN病例的流行病学、治疗、产前和围产期结局以及患者病程的文章。对参考文献和灰色文献进行滚雪球式搜索以补充初始搜索。对英文、西班牙文和葡萄牙文的出版物进行了综述。使用定义的模板提取数据并制成表格。

结果

我们回顾了来自巴西、智利、墨西哥、阿根廷、哥伦比亚、巴拿马、巴拉圭和秘鲁的5项指南和19项观察性研究。Rh同种免疫导致的HDFN发生率为每1000例活产0.5至5例,抗-D仍然是严重HDFN最常见的同种抗体类型。HDFN的围产期死亡率约为每10万例活产1.3 - 1.6例,在接受宫内输血治疗的患者中,胎儿死亡率可达30%。高达47%的同种免疫妊娠仅在妊娠晚期才被转诊至参考中心。约60%的符合条件的妊娠接受了抗-D IgG预防。

结论

尽管拉丁美洲国家的估计数据稀少且缺乏标准化措施,但我们观察到该地区HDFN的发病率、发病率和死亡率都存在问题。尽管抗-D HDFN在很大程度上是可预防的,但在约70%的严重HDFN病例中报告了RhD同种免疫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c7a/11660609/304118d4609a/12884_2024_7044_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验